No Detail Found!

Role of leuprorelin on ovarian function of patients with receptor- positive premenopausal breast cancer

Author(s)
Dan Sun Gynecology Department II, Cangzhou Central Hospital,Cangzhou,China
Yingchun Li Gynecology Department II, Cangzhou Central Hospital,Cangzhou,China
Xiaoyu Zhang Department of Thyroid and Breast III, Cangzhou Central Hospital,Cangzhou,China
Abstract
This study aims to investigate the clinical efficacy of leuprorelin on ovarian function in premenopausal breast cancer (PBC) with positive Estrogen or Progesterone receptor. Forty receptor-positive PBC patients admitted to our hospital from January 2018 to October 2020 were randomized into control group and observation group, with 20 cases in each group. Tamoxifen and tamoxifen plus leuprorelin was respectively applied. The levels of bFSH and bAFC, total effective rate, survival rate at 6, 18 and 30 months, adverse reactions, the quality of life and activity of life scores were recorded and compared. After treatment, bFSH and bAFC in the observation group group were better. The total effective rate was 90.00% in the observation group and 55.00% in the control group. The survival rate of 18 and 30 months in the observation group was notably higher while the incidence of adverse reactions was lower. The quality of life score and activity of life score in the observation group were higher. Leuprorelin combined with endocrine drugs can obviously protect ovarian function with significant long-term effect, which effectively reduces the impact of adverse reactions on receptor-positive PBC patients, with higher safety and better feasibility.
Publication Details
Page(s) 2379-2383
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: SUP6, Year: 2021

Request the full text from PASTIC

Keywords
receptor positive, premenopausal breast cancer patients, Ovarian function, Leuprorelin, Adverse reaction
References
Bui KT,Willson ML,Goel S,Beith J,Goodwin A .2020 .Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochrane Database Syst. Rev., 3(3) : CD013538.
Cheng Y,Li N,Eapen A,Parajuli R,Mehta R .2019 .Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in PlatinumExposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC. Case Rep. Oncol., 12(2) : 494-499.
Giuliano M,Schettini F,Rognoni C,Milani M,Jerusalem G,Bachelot T,Generali D .2019 .Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2- negative, metastatic breast cancer: A systematic review and network meta-analysis. Lancet Oncol., 20(10) : 1360-1369.
Goto R,Uda A,Hiroi S,Iwasaki K,Takashima K,Kurebayashi J .2017 .Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations. J. Med, 20(11) : 1163-1169.
Han W and Youn HJ .2019 .Clinical studies investigating the use of leuprorelin in breast cancer patients from Asia. Asian Pac. J. Cancer Prev, 20(5) : 1475-1479.
Hannah-Shmouni F,Moraitis AG,Romero VV,Faucz FR,Mastroyannis SA,Berthon A,Stratakis CA .2018 .Successful treatment of estrogen excess in primary bilateral macronodular adrenocortical hyperplasia with leuprolide acetate. Horm. Metab. Res., 50(2) : 124-132.
Hansra D,Jackson S,Sequeira J,Vazirani R,Alvarez R .2020 .Male patient with metastatic stage IV breast cancer achieves complete remission on second line abemaciclib, fulvestrant and leuprolide: A case report. Mol. Clin. Oncol., 12(2) : 120-125.
Kendzierski DC,Schneider BP,Kiel PJ .2018 .Efficacy of different leuprolide administration schedules in premenopausal breast cancer: A retrospective review. Clin. Breast Cancer, 18(5) : e939-e942.
Kojima N,Yamasaki Y,Koh H,Miyashita M,Morita H M .2018 .Long-acting luteinizing hormone-releasing hormone agonist for ovarian hyperstimulation induced by tamoxifen for breast cancer. Case Rep. Obstet. Gynecol., 4931852 : .
Kurebayashi J,Toyama T,Sumino S,Miyajima E,Fujimoto T .2017 .Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: A phase III, randomized, open-label, parallel-group comparative study. Breast Cancer, 24(1) : 161-170.
Lee J,Im SA,Kim GM,Jung KH,Kang SY,Park IH,Park YH .2021 .Implications of tamoxifen resistance in palbociclib efficacy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer: Subgroup analyses of KCSG-BR15-10 (YoungPEARL). Cancer Res. Treat., 53(3) : 695-702.
Li T,Mello-Thoms C,Brennan PC C .2016 .Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Breast Cancer Res. Treat., 159(3) : 395-406.
Mistry R,May JR,Suri G,Young K,Brixner D,Oderda G .2018 .Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+/HER2-advanced or metastatic breast cancer: A U.S. payer perspective. J. Manag. Care Spec Pharm., 24(6) : 514-523.
Ozaki Y,Tanabe Y,Tamura N,Ogura T,Kondoh C,Miura Y,Takano T Y .2018 .Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: A retrospective single-institution study. Breast Cancer, 25(3) : 343-349.
Park YH,Kim TY,Kim GM,Kang SY,Park IH,Kim JH,Im SA .2019 .Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): A multicentre, open-label, randomised, phase 2 trial. , 20(12) : 1750-1759.
Sansone P,Ceccarelli C,Berishaj M,Chang Q,Rajasekhar VK,Perna F,Bromberg J F .2016 .Selfrenewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat. Commun, 7 : 10442.
Strini V,Piazzetta N,Gallo A,Schiavolin R .2020 .Barthel Index: creation and validation of two cut-offs using the BRASS Index. , 91 : 19-26.
Tanios G,Mungo NA,Kapila A,Bajaj K A .2017 .Pituitary apoplexy: A rare complication of leuprolide therapy in prostate cancer treatment. BMJ. Case Rep., bcr2016218514., : .
Taylor-Stokes G,Mitra D,Waller J,Gibson K,Milligan G,Iyer S G .2019 .Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study. Breast, 43 : 22-27.
von Hippel C,Rosenberg SM,Austin SB,SprunckHarrild K,Ruddy KJ,Schapira L,Partridge AH .2019 .Identifying distinct trajectories of change in young breast cancer survivors sexual functioning. Psychooncology, 28(5) : 1033-1040.
Waller J,Mitra D,Mycock K,Taylor-Stokes G,Milligan G,Zhan L,Iyer S L .2019 .Real-world treatment patterns and clinical outcomes in patients receiving palbociclib for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in Argentina: The IRIS study. J. Glob Oncol., 5 : Jgo1800239.
Zhang P,Li CZ,Jiao GM,Zhang JJ,Zhao HP,Yan F,Jia SF,Hu BS,Wu CT .2017 .Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trials. Eur. J. Surg, 43(7) : 1161-1172.
Zhu J,Davis CT,Silberman S,Spector N,Zhang T .2016 .A role for the androgen receptor in the treatment of male breast cancer. Crit. Rev. Oncol. Hematol, 98 : 358-363.
0

Citations

0

Downloads

12

Views